Oramed Pharmaceuticals (Israel) Valuation Overview

ORMP -- Israel Stock  

null 1,732  108.00  5.87%

Oramed Pharmaceuticals recent Real Value cannot be determined due to lack of data. The prevailing price of Oramed Pharmaceuticals is 1732.0. Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Macroaxis determines value of Oramed Pharmaceuticals from analyzing the company fundamentals such as Revenue of 2.45M, Current Valuation of 268.15M and Return On Equity of (68.54)% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Horizon     30 Days    Login   to change

Oramed Pharmaceuticals Total Value Analysis

Oramed Pharmaceuticals is now anticipated to have takeover price of 268.15 M with market capitalization of 290.34 M, debt of 0, and cash on hands of 23.37 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Oramed Pharmaceuticals fundamentals before making investing decisions based on the enterprise value of the company

Oramed Pharmaceuticals Investor Information

The company recorded loss per share of 0.88. Oramed Pharmaceuticals had not issued any dividends in recent years. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel. Oramed Pharmaceuticals is traded on Tel Aviv Stock Exchange in Israel. To find out more about null contact Nadav Kidron at 972 2 566 0001 or learn more at http://www.oramed.com.

Oramed Pharmaceuticals Asset Utilization

Oramed Pharmaceuticals holds negative application of asset of -22.21 pct., making only 0.22 for each of asset held by the company. Inadequate assets utilization implies the company is being less effective with each of asset it holds. In other words assets utilization of Oramed Pharmaceuticals shows how discouraging it operates for each spent on its asset.

Oramed Pharmaceuticals Profitability Analysis

The company reported revenue of 2.45 M. Net Loss for the year was (12.5 M) with profit before overhead, payroll, taxes, and interest of 2.27 M.
 Profitability 
      Values 

Current Market Valuation

Oramed Pharmaceuticals Valuation Boundaries

Not valued
October 22, 2018
1,732
Market Value
0.00
Real Value
Target Odds
  
0.00
Upside
Oramed Pharmaceuticals is Unknown risk asset. Calculation of real value of Oramed Pharmaceuticals is based on 1 month time horizon. Increasing Oramed Pharmaceuticals time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Additionally take a look at Your Equity Center. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Search macroaxis.com